Status:
COMPLETED
Benefits of Trimetazidine in MASLD Patients
Lead Sponsor:
October 6 University
Conditions:
Metabolic Associated Fatty Liver Disease
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MASLD
Detailed Description
the study will evaluate the possible benefits of trimetazidine when added to pateints with metabolic associated fatty liver disease
Eligibility Criteria
Inclusion
- participants were included if they met MASLD diagnostic criteria, which required imaging-confirmed hepatic steatosis (via abdominal ultrasound and CAP), along with metabolic factors (BMI ≥25 kg/m², diabetes/dysglycemia, blood pressure ≥130/85 mmHg, triglycerides ≥150 mg/dL, or reduced HDL-cholesterol)
Exclusion
- The study excluded those with
- alternative steatosis causes (alcohol intake \>50 g/day women or \>60 g/day men
- drug-induced injury, hepatitis C, Wilson disease).
- Additional exclusion criteria covered ages below 18 years, pregnancy. decompensated cirrhosis, portal hypertension, hepatocellular carcinomas.
- Trimetazidine contraindications (Parkinson's disease, parkinsonian symptoms, tremors, severe renal impairment), patients on statins, sodium glucose transporter 2 inhibitors (SGLT2), glucagon-like peptide 1(GLP1) were among the other exclusion criteria
Key Trial Info
Start Date :
December 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06140953
Start Date
December 10 2023
End Date
November 30 2024
Last Update
July 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beni-Suef university
Banī Suwayf, Beni Suweif Governorate, Egypt, 62511